ACTRN12613001324707尚未招募1 期
Feasibility of administrating a low dose anti coagulant in critically ill patients undergoing Extracorporeal Membrane Oxygenation: a pilot study
Alfred Hospital0 个研究点目标入组 20 人开始时间: 2013年12月2日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Prevention
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 16 Years 至 o limit（—）
- 性别
- All
入选标准
- •patients hospitalised in intensive care unit who require ECMO or on ECMO for less than 48 hours.
排除标准
- •Age younger than 16 years
- •Known objection to the administration of human blood products
- •Participation in a competing study on anticoagulation
- •Heparin-induced thrombocytopenia
- •Any pre-existing indication for prolonged full dose anti-coagulation: long-term warfarin for atrial fibrillation), pulmonary emboli, deep venous thrombosis, intra-cardiac thrombus
研究者
相似试验
已完成
不适用
The feasibility of using a subtherapeutic dose of piracetam as a marker of adherence to therapyDe studie wordt uitgevoerd in gezonde vrijwilligers met als doel te onderzoeken of er een meetbare concentratie piracetam in de urine ontstaat na subtherapeutisch dosering piracetam. Er wordt dus geen effect op een aandoening onderzocht.n.v.t. (zie uitleg onder vraag C21)NL-OMON53199ederlands Kanker Instituut10
进行中（未招募）
不适用
therapy antiedemigena through administration of corticosteroidi after surgical extraction of the teeth of the judgment. - NDEUCTR2010-021295-28-ITAZIENDA OSPEDALIERA MAGGIORE DELLA CARITA` DI NOVARA
已完成
2 期
the effect of plavix in post coronary artery bypass graft/coronary endarterectomy patientsCoronary artery disease.Atherosclerotic heart disease Coronary (artery): atheroma atherosclerosis disease sclerosisIRCT2016102730410N2Babol University of Medical Sciences, Deputy of Research & Technology55
招募中
1 期
The effect of coagulation factors on the reduction of joint/ non-joint bleeding and the consumption of coagulation factor in patients with severe A hemophiliaHemophilia.Hereditary factor VIII deficiencyIRCT20170211032495N1Vice chancellor for research of Tehran University of Medical Sciences15
进行中（未招募）
不适用
PRETREATMENT WITH HIGH DOSE CLOPIDOGREL FOR REDUCTION OF THROMBOTIC EVENTS AFTER ELECTIVE CORONARY TERRITORY STENTING WITH DRUG ELUTING STENTS: ThePROTECTED Study - The PROTECTED StudyPERCUTANEOUS CORONARY INTERVENTION( USING DRUG ELUTING STENTS)EUCTR2004-000517-19-GBBlackpool Fylde & Wyre Healthcare NHS Trust100